Rate of conversion from unresectable to resectable metastatic colorectal cancer (mCRC) in real-world patients (RWP) treated with FOLFIXIRI ± bevacizumab: A population-based retrospective cohort study.

Tayyaba Bhatti,Michael A. J. Moser,Jon Tan,Adnan Zaidi,Duc Le,Haji I. Chalchal,John Shaw,Selliah Kanthan,Mussawar Iqbal,Yigang Luo,Kamal Haider,Tehmina Asif,Dueck Dorie-Anna,Dilip Gill,Nathan Ginther,Shahid Ahmed

Rate of conversion from unresectable to resectable metastatic colorectal cancer (mCRC) in real-world patients (RWP) treated with FOLFIXIRI ± bevacizumab: A population-based retrospective cohort study.

2020

Tayyaba Bhatti
Michael A. J. Moser
Jon Tan
Adnan Zaidi
Duc Le
Haji I. Chalchal
John Shaw
Selliah Kanthan
Mussawar Iqbal
Yigang Luo
Kamal Haider
Tehmina Asif
Dueck Dorie-Anna
Dilip Gill
Nathan Ginther
Shahid Ahmed

21Background: Recent evidence from randomized trials suggests that FOLFOXIRI (5FU, oxaliplatin, and irinotecan) ± bevacizumab is associated with higher response rates with a potential for conversio...

Keywords:

Irinotecan
FOLFOXIRI
Internal medicine
Oxaliplatin
Bevacizumab
Physical therapy
population based
Medicine
Randomized controlled trial
Oncology
Colorectal cancer
Retrospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations